SER 101

Drug Profile

SER 101

Alternative Names: RO1160367; SER101

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in Europe
  • 13 Dec 2010 Phase-I clinical trials in Congestive heart failure in Europe (unspecified route)
  • 13 Dec 2010 Roche grants Serodus exclusive worldwide development, manufacturing and commercialisation rights for its serotonin 4 receptor antagonist for the treatment of heart failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top